SEATTLE, March 29, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering India Globalization Capital Inc.'s (NYSE American:IGC) (“IGC”) recent announcement that they are launching Hyalolex, the company’s flagship cannabinoid-based combination therapy supplement for Alzheimer’s disease, in Puerto Rico. IGC signed an agreement with DaMa Pharmaceutical to distribute Hyalolex in 10 of the 30 medical dispensaries in Puerto Rico. It begs the question why Puerto Rico and not one of the many states that have legalized medical marijuana?
Alzheimer’s is a devastating disease that affects more than 5.5 million Americans and over 40 million people worldwide with no cure. At a cost of over $277 billion to Medicare and Medicaid each year, it’s also widely considered to be the country’s most expensive disease.
The Latino population will grow to about 129 million by 2016, or about 31 percent of the nation’s population, making it America’s largest minority group, according to usagainstalzheimers.org. The likelihood of getting Alzheimer’s doubles about every 5 years, after 65, reaching about 50% by the age of 85. Due to several underlying factors, Latinos are about 50% more likely to develop Alzheimer’s than Caucasians. Due to the rapidly aging population in the Latino community, the cost associated with Alzheimer’s and the cost associated with caregivers is predicted to skyrocket over the coming years.
Since Puerto Rico has a large Latino population, the company has decided to launch Hyalolex in the territory before rolling it out to the wider United States. The company also plans to fine-tune its Spanish language messaging, customer care, website, marketing materials, and other supporting activities before launching into Latino markets in California, Florida, New York, and Texas (when legal). This approach is similar to that of large pharmaceutical companies. Culturally, Latinos also prefer natural non-Western medicine over traditional medicine.
IGC’s Hyalolex is a twice-or thrice-daily liquid supplement that’s designed for patients suffering from mild to advanced Alzheimer’s disease. In early studies, the medication has been shown to inhibit the formation of harmful plaques and tangles - two hallmarks of Alzheimer’s. The supplement has also been shown to enhance mitochondrial function, reduce inflammation, and modulate other Alzheimer’s symptoms like anxiety, agitation, and sleep disorder. These benefits could also reduce stress for caregivers, which is a major cost when treating the disease.
In addition to commercializing its most advanced product, the company hopes to collect data on Hyalolex’s performance within a diverse patient set for its future clinical trials. The company plans to do this by deploying a QR-code based product assurance, information dissemination, and data collection system.
Looking Ahead
India Globalization Capital Inc. (NYSE MKT:IGC) represents a unique opportunity within the multi-billion dollar Alzheimer’s disease market. The company is strategically positioned as the only cannabis based pharmaceutical company in the Alzheimer’s space. By targeting a niche market and setting up a distribution to productize its intellectual property into many of the larger markets, the company is uniquely positioned to grow long-term shareholder value. IGC has patents filed for formulations for Parkinson’s, PTSD, pain, epilepsy in cats and dogs, among others, as potential products that it can bring to market.
For more information, visit the company’s corporate website or its product website.
Please follow the link to read the full article: http://www.cannabisfn.com/india-globalization-capital-igc-launches-hyalolex-alzheimers/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Frank Lane
206-369-7050
flane@cannabisfn.com